In Week of Mar 28, 2026, Accent Microcell Ltd (Pharma - Formulators) is outperforming Nifty 500 with +28.1% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: New SMCC, Spheres and powder cellulose products already contributing 5-7% incremental revenue with direct margin flow-through
Impact: +₹13.25 Cr revenue
“Management stated: 'Incremental increase in the price so roughly, you can say around say, 5 to 7 percentage increase in the sales of finished goods because of the new range that we have started selling off'”
What: Premium exhibition product line launch with significantly higher realization per kg compared to MCC
“Management stated: 'Phase one will be in say, it will be a premium range of exhibition product. So margin will be on quote quite higher side as compared to MCC. And for phase 2, we are coming out with a plan of MCC. So the margin will be on similar lines.'”
What: Growing international business providing revenue diversification and potential pricing advantages
“Management confirmed: 'Exports currently is a 65% of your business. So, I think, FY25, we closed with 53%.'”
Earnings deceleration risks from management commentary
Trigger: Failure to achieve order book and customer satisfaction targets
Management view: Management links capacity expansion to 'successful achievement of the order book and the customer satisfaction level' before proceeding with Unit 3.
Monitor: Quarterly utilization rates for Unit 3 Phase 1
Trigger: Significant INR appreciation against major currencies
Management view: Not explicitly addressed in available transcripts
Monitor: Export revenue growth vs forex rates
Key quotes from recent conference calls
“Incremental increase in the price so roughly, you can say around say, 5 to 7 percentage increase in the sales of finished goods because of the new range that we have started selling off, namely, SMCC, Spheres powder cellulose, and other combination co-process. MCC. — Ghanshyam Patel”
“Sir EBITDA margin was around 16% going ahead as we are coming out with unique 3 in phase, manner, that is phase one and phase 2. Phase one will be in say, it will be a premium range of exhibition product. So margin will be on quote quite higher side as compared to MCC. — Ghanshyam Patel”
“Blended margins, as you rightly mentioned is 20 to 22% — Ghanshyam Patel”
“I can share you the say, rough idea about the total capex for entire unit 3 as of now, that is phase 1 phase 2, except the land portion, I think. It will be around say, it will be anywhere between 105 to 110 cr. — Ghanshyam Patel”
Forward-looking targets from management for FY27
OPM Guidance
20%
Capex Plan
₹110 Cr
Key Milestones
• 70% utilization of Unit 3 Phase 1 in FY27
• 20-22% blended EBITDA margins
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +10% | +17% | Stable |
| PAT (Net Profit) | +13% | +77% | Stable |
| OPM | 17.0% | +200 bps | Stable |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Accent Microcell Ltd's latest quarterly results (Sep 2025) show
Accent Microcell Ltd's profit is growing with an stable trend.
Accent Microcell Ltd's revenue growth trend is stable.
Accent Microcell Ltd's operating margin is stable.
Accent Microcell Ltd's long-term compounding rates
Accent Microcell Ltd's earnings growth is stable with mixed signals on a sequential basis.
Accent Microcell Ltd appears significantly undervalued based on our fair value analysis.
Accent Microcell Ltd's current PE ratio is 25.7x.
Accent Microcell Ltd's current PE is 25.7x.
Accent Microcell Ltd's price-to-book ratio is 3.6x.
Accent Microcell Ltd is rated Average with a fundamental score of 58.5/100. This score is calculated from objective financial metrics
Accent Microcell Ltd has a debt-to-equity ratio of N/A.
Accent Microcell Ltd's return ratios over recent years
Accent Microcell Ltd's operating cash flow is positive (FY2025).
Accent Microcell Ltd's current dividend yield is 0.27%.
Accent Microcell Ltd's shareholding pattern (Dec 2025)
Accent Microcell Ltd's promoter holding has remained stable recently.
Accent Microcell Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Accent Microcell Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Accent Microcell Ltd has 3 key growth catalysts identified from recent earnings analysis
Accent Microcell Ltd has 2 key risks worth monitoring
In Q3 FY26, Accent Microcell Ltd's management highlighted
Accent Microcell Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Accent Microcell Ltd may be worth studying
Accent Microcell Ltd investment thesis summary:
Accent Microcell Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
